Bob Bradway, Amgen CEO (Justin Kase Conder/AP Images for Amgen)

Am­gen en­lists TCR start­up TScan to work on Crohn's in deal po­ten­tial­ly worth $500M+

Am­gen is tak­ing a clos­er look at us­ing T cells for in­flam­ma­tion, an­nounc­ing a new deal Tues­day with TCR up­start TScan Ther­a­peu­tics.

The com­pa­nies will team up to dis­cov­er new tar­gets for Crohn’s dis­ease, and Am­gen has the op­tion to ex­pand the agree­ment in­to ul­cer­a­tive col­i­tis. Am­gen is pay­ing $30 mil­lion up­front to use TScan’s plat­form for ex­am­in­ing how T cells in­ter­act with anti­gens in Crohn’s, and is promis­ing more than $500 mil­lion in biobucks as well as sin­gle-dig­it roy­al­ties.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.